Achieving Cannabis Cessation — Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Despite recent advances in behavioral interventions for cannabis use disorders, effect sizes remain modest, and few individuals achieve long-term abstinence. One strategy to enhance outcomes is the addition of pharmacotherapy to complement behavioral treatment, but to date no efficacious medications targeting cannabis use disorders in adults through large, randomized controlled trials have been identified. The National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) is currently conducting a study to test the efficacy of N-acetylcysteine (NAC) versus placebo (PBO), added to contingency management, for cannabis cessation in adults (ages 18–50). This study was designed to replicate positive findings from a study in cannabis-dependent adolescents that found greater odds of abstinence with NAC compared to PBO. This paper describes the design and implementation of an ongoing 12-week, intent-to-treat, double-blind, randomized, placebo-controlled study with one follow-up visit four weeks post-treatment. Approximately 300 treatment-seeking cannabis-dependent adults will be randomized to NAC or PBO across six study sites in the United States. The primary objective of this 12-week study is to evaluate the efficacy of twice-daily orally-administered NAC (1200 mg) versus matched PBO, added to contingency management, on cannabis abstinence. NAC is among the first medications to demonstrate increased odds of abstinence in a randomized controlled study among cannabis users in any age group. The current study will assess the cannabis cessation efficacy of NAC combined with a behavioral intervention in adults, providing a novel and timely contribution to the evidence base for the treatment of cannabis use disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse health effects of non-medical cannabis use
Hall, W., & Degenhardt, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61037-0 · Cited by 1,134
Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen Overdose
Smilkstein, M. J., Knapp, G. L., Kulig, K. W., & Rumack, B. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192401 · Cited by 1,102
Farmer, K. C. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80026-5 · Cited by 889
Comparison of extended versus brief treatments for marijuana use.
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.898 · Cited by 711
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434 · cited 12×
“NAC may have the potential to be used in the treatment of several psychiatric disorders [46] and SUDs [47], though not all randomized trials have yielded positive results with NAC [105, 106].”
InfluentialA Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to Adulthood
Wilens, T. E., & Spencer, T. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2206 · Cited by 324 · cited 1×
“This was considered appropriate for feasibility purposes, given the high frequency of co-occurrence of ADHD and SUDs among young adults [73, 74].”
A Double-Blind Randomized Controlled Trial of N -Acetylcysteine in Cannabis-Dependent Adolescents
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306 · cited 10×
“Additionally, given the positive primary outcome noted in the adolescent study, which used an escalating cash-based CM schedule with resets [16], the Lead Investigators and protocol development team determined that it would be prudent to closely mirror that study’s CM design.”
InfluentialSelf-citationBudney, A. J., Moore, B. A., Rocha, H. L., & Higgins, S. T. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.4.2.307 · Cited by 290
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266 · cited 1×
“Several promising agents to treat CUDs exist [16, 17], but to date, an effective medication targeting cannabis dependence in adults has not been established [12, 14, 18, 19], leaving clinicians and patients with limited options.”
Internet-delivered treatment for substance abuse: a multisite randomized controlled trial
Campbell, A. N. C., Nunes, E. V., Matthews, A. G., Stitzer, M., Miele, G. M., Polsky, D., Turrigiano, E., Walters, S., McClure, E. A., Kyle, T. L., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13081055 · Cited by 263
Self-citationMason, B. J., Crean, R., Goodell, V., Light, J. M., Quello, S., Shadan, F., Buffkins, K., Kyle, M., Adusumalli, M., Begovic, A., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.14 · Cited by 242
Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232 · cited 1×
“Several promising agents to treat CUDs exist [16, 17], but to date, an effective medication targeting cannabis dependence in adults has not been established [12, 14, 18, 19], leaving clinicians and patients with limited options.”
Self-citationZhou, W., & Kalivas, P. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.008 · Cited by 225
Repeated N-Acetylcysteine Administration Alters Plasticity-Dependent Effects of Cocaine
Madayag, A., Lobner, D., Kau, K. S., Mantsch, J. R., Abdulhameed, O., Hearing, M., Grier, M. D., & Baker, D. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2808-07.2007 · Cited by 225
Zulauf, C. A., Sprich, S. E., Safren, S. A., & Wilens, T. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-013-0436-6 · Cited by 214 · cited 1×
“This was considered appropriate for feasibility purposes, given the high frequency of co-occurrence of ADHD and SUDs among young adults [73, 74].”
Carroll, K. M., Easton, C. J., Nich, C., Hunkele, K. A., Neavins, T. M., Sinha, R., Ford, H. L., Vitolo, S. A., Doebrick, C. A., & Rounsaville, B. J. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.5.955 · Cited by 214
Self-citationReliability and validity of a short form of the Marijuana Craving Questionnaire
Heishman, S. J., Evans, R. J., Singleton, E. G., Levin, K. H., Copersino, M. L., & Gorelick, D. A. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.12.010 · Cited by 212
A double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187
Missing Data in Alcohol Clinical Trials: A Comparison of Methods
Hallgren, K. A., & Witkiewitz, K. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12205 · Cited by 176 · cited 1×
“Several strategies will be evaluated to determine the optimal method for dealing with missing data, including sophisticated imputation methods that have been recommended for alcohol clinical trials [96].”
Abstinence rates following behavioral treatments for marijuana dependence
Kadden, R. M., Litt, M. D., Kabela-Cormier, E., & Petry, N. M. (2007) · Addictive Behaviors · doi:10.1016/j.addbeh.2006.08.009 · Cited by 173
Schmidt, L. E., & Dalhoff, K. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01305.x · Cited by 127 · cited 1×
“Participants with a recent history of asthma (last 3 years) are excluded since allergic reactions to intravenous NAC have been shown to be more likely in those with asthma [75].”
Treatment of marijuana dependence: a review of the literature.
McRae, A. L., Budney, A. J., & Brady, K. T. (2003) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(03)00041-2 · Cited by 115 · cited 1×
“, contingency management, relapse prevention, motivational interviewing, cognitive behavioral therapy, and combinations) compared to control conditions [6], yet there remains substantial room for improvement, as the majority of patients fail to achieve sustained periods of abstinence [7–9].”
Davis, M. L., Powers, M. B., Handelsman, P., Medina, J. L., Zvolensky, M., & Smits, J. A. J. (2015) · Evaluation & the Health Professions · doi:10.1177/0163278714529970 · Cited by 114 · cited 1×
“, contingency management, relapse prevention, motivational interviewing, cognitive behavioral therapy, and combinations) compared to control conditions [6], yet there remains substantial room for improvement, as the majority of patients fail to achieve sustained periods of abstinence [7– 9].”
Cited by
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
“…use disorder Grant et al., 2010 Tobacco use disorder Open label 19 Combination treatment reduces cigarettes smoked per day with minimal side effects McClure et al., 2014a,b Tobacco use disorder Laboratory trial 22 NAC decreases subjective reward after experimentally delivered cigarette Schmaal et…”
BackgroundA randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray, K. M., Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.04.020 · Cited by 157
“2.3 General Procedures Details of study design have been described previously (McClure et al., 2014).”
BackgroundMethodSelf-citationPharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Hser, Y.-I., Mooney, L. J., Huang, D., Zhu, Y., Tomko, R. L., McClure, E., Chou, C.-P., & Gray, K. M. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.07.012 · Cited by 127
Self-citationPharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Metadata
- Authors
- McClure, E. A., Sonne, S. C., Winhusen, T., Carroll, K. M., Ghitza, U. E., McRae-Clark, A. L., Matthews, A. G., Sharma, G., Van Veldhuisen, P., Vandrey, R. G., Levin, F. R., Weiss, R. D., Lindblad, R., Allen, C., Mooney, L. J., Haynes, L., Brigham, G. S., Sparenborg, S., Hasson, A. L., & Gray, K. M.
- Venue
- Contemporary Clinical Trials
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 39
- Issue
- 2
- Pages
- 211-223
- ISSN
- 1551-7144 (ISSN-L)
- OpenAlex
- W2001253512
- Cited by
- 50
- References
- 24
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.